501 related articles for article (PubMed ID: 16605111)
1. Parasitological, hematological and ultrastructural study of the effect of COX-2 inhibitor, pyocyanin pigment and praziquantel, on S. mansoni infected mice.
Mohamed AH; Ezz El-Din N; Fahmy ZH; El-Shennawy AM; Hassan E
J Egypt Soc Parasitol; 2006 Apr; 36(1):197-220. PubMed ID: 16605111
[TBL] [Abstract][Full Text] [Related]
2. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy GH
J Egypt Soc Parasitol; 2009 Aug; 39(2):687-701. PubMed ID: 19795775
[TBL] [Abstract][Full Text] [Related]
3. Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.
El-Lakkany NM; El-Maadawy W; Ain-Shoka A; Badawy A; Hammam O; Ebeid F
Clin Exp Pharmacol Physiol; 2011 Oct; 38(10):695-704. PubMed ID: 21762203
[TBL] [Abstract][Full Text] [Related]
4. Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment.
Botros SS; Hammam O; Mahmoud M; Bergquist R
APMIS; 2010 Sep; 118(9):692-702. PubMed ID: 20718722
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment.
Chaiworaporn R; Maneerat Y; Rojekittikhun W; Ramasoota P; Janecharut T; Matsuda H; Kitikoon V
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):846-52. PubMed ID: 16295535
[TBL] [Abstract][Full Text] [Related]
6. Antischistosomal effects of praziquantel, its alkaline hydrolysis and sun decomposed products on experimentally S. mansoni infected albino mice. (A) Efficacy assessment based on clinicopathological findings.
Suleiman MI; Akarim EI; Ibrahim KE; Saad AM; Mohammed AE; Ahmed BM; Sulaiman SM
J Egypt Soc Parasitol; 2004 Apr; 34(1):131-42. PubMed ID: 15143740
[TBL] [Abstract][Full Text] [Related]
7. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay.
Frezza TF; Gremião MP; Zanotti-Magalhães EM; Magalhães LA; de Souza AL; Allegretti SM
Acta Trop; 2013 Oct; 128(1):70-5. PubMed ID: 23811113
[TBL] [Abstract][Full Text] [Related]
8. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure.
Sabra AN; Botros SS
J Parasitol; 2008 Apr; 94(2):537-41. PubMed ID: 18564758
[TBL] [Abstract][Full Text] [Related]
9. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.
Liang YS; Coles GC; Dai JR; Zhu YC; Doenhoff MJ
J Helminthol; 2002 Dec; 76(4):327-33. PubMed ID: 12498638
[TBL] [Abstract][Full Text] [Related]
10. Anthelmintic activity in vitro and in vivo of Baccharis trimera (Less) DC against immature and adult worms of Schistosoma mansoni.
de Oliveira RN; Rehder VL; Oliveira AS; Jeraldo Vde L; Linhares AX; Allegretti SM
Exp Parasitol; 2014 Apr; 139():63-72. PubMed ID: 24602876
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of a Brazilian wild rodent isolate of Schistosoma mansoni to praziquantel in mice.
Costa-Silva M; Barros Lde A; Garcia JS; Neves RH; Rodrigues-Silva R; Machado-Silva JR; Maldonado-Júnior A
Exp Parasitol; 2012 Apr; 130(4):394-9. PubMed ID: 22343042
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and bioavailability of different praziquantel brands.
Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
[TBL] [Abstract][Full Text] [Related]
13. Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates.
Botros S; Mahmoud M; Hammam O; Salah F; Zidek Z; Masek K
APMIS; 2006; 114(7-8):480-91. PubMed ID: 16907853
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
Lotfy WM; Hishmat MG; El Nashar AS; Abu El Einin HM
Pharm Biol; 2015 Aug; 53(8):1214-9. PubMed ID: 25609146
[TBL] [Abstract][Full Text] [Related]
15. Studies on parasitologic and haematologic activities of an enaminone derivative of 4-hydroxyquinolin-2(1H)-one against murine schistosomiasis mansoni.
El-Shennawy AM; Mohamed AH; Abass M
MedGenMed; 2007 Jan; 9(1):15. PubMed ID: 17435624
[TBL] [Abstract][Full Text] [Related]
16. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities.
Botros SS; El-Din SH; El-Lakkany NM; Sabra AN; Ebeid FA
J Parasitol; 2006 Dec; 92(6):1344-9. PubMed ID: 17304818
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt.
Barakat R; El Morshedy H
Parasitology; 2011 Apr; 138(4):440-6. PubMed ID: 21078223
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of alpha lipoic acid combined with praziquantel on liver fibrosis induced by Schistosoma mansoni challenged mice.
Abdel-Hafeez EH; Ahmad AK; Abdulla AM; Aabdel-Wahab S; Mosalem FA
Parasitol Res; 2012 Aug; 111(2):577-86. PubMed ID: 22398831
[TBL] [Abstract][Full Text] [Related]
19. Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination.
William S; Botros S
Int J Parasitol; 2004 Jul; 34(8):971-7. PubMed ID: 15217736
[TBL] [Abstract][Full Text] [Related]
20. Resistance to praziquantel, effect of drug pressure and stability test.
Ismail MM; Farghaly AM; Dyab AK; Afify HA; el-Shafei MA
J Egypt Soc Parasitol; 2002 Aug; 32(2):589-600. PubMed ID: 12214936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
